FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667079> ?p ?o ?g. }

• W4385667079 endingPage "e3528996" @default.
• W4385667079 startingPage "e3528996" @default.
• W4385667079 abstract "Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder. In the UK, Germany, and France, C5 complement inhibitors, such as eculizumab and ravulizumab, both of which are intravenously (IV) infused, are the standard of care for PNH. Aims: The COMMODORE Burden of Illness study aims to quantify the real-life socioeconomic burden of PNH. We present results from the first study phase, for participants from the UK, Germany, and France, focusing on those receiving IV C5 inhibition treatment. Methods: Physicians completed Case Report Forms (CRFs) collecting information on clinical characteristics of the disease, at study enrollment. Following physician invitation, adult participants (≥18 years old) diagnosed with PNH ≥12 months prior to enrollment, and their caregivers, could complete patient-reported outcomes (PROs) and caregiver-reported outcome questionnaires, respectively. The clinical patient characteristics included PNH subtype and clinical events in the last 12 months. Patient questionnaires (PROs) included Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue), Patient Global Impression of Severity (PGI-S), Quality-of-Life Tool for Patients with Aplastic Anaemia and/or PNH (QLQ-AA/PNH-54), and 5-level EuroQoL 5-dimension (EQ-5D-5L). Caregiver questionnaires included the Carer Experience Scale (CES) and the Short Form 6 Dimension (SF-6Dv2.0). The economic burden was categorized as costs to the healthcare system (from the CRFs), costs to patients (from the Patient Questionnaires), and costs to caregivers (from the Caregiver Questionnaires). See table for cost types. Analyses were descriptive, and results are presented as n (%) or mean (range/standard deviation [SD]). Results: In total, 150 participants across all three countries treated with C5 inhibition were analyzed, comprising 150 CRFs, 58 Patient Questionnaires, and 33 Caregiver Questionnaires. The mean age at enrollment was 41.0 (range 20‒76) years, and the majority of participants were male (68.7%); 92.6% had classic PNH, and 7% had PNH with another bone marrow disease. Most participants received eculizumab as treatment (72.7%) vs ravulizumab (24.0%); while 3.3% switched from eculizumab to ravulizumab. 41.3% of the participants reported at least one thrombotic event and 50.7% experienced hemolysis in the prior 12 months. Patients (n=58) reported a mean FACIT-Fatigue score of 28.2 (SD 6.5); a mean PGI-S score of 4.5 (SD 2.3); for the QLQ-AA/PNH-54, the highest mean scores (indicating worse QoL) were associated with the “emotional functioning”, and the “cognitive functioning” components (69.3 [SD 16.9], and 68.1 [SD 17.4], respectively); and the mean EQ-5D-5L utility and visual analogue scale scores were 0.81 (SD 0.2), and 62.0 (SD 19.3), respectively. Caregivers (n=33) reported a mean CES score of 68.9 (SD 19.8) and a mean SF-6Dv2.0 utility score of 0.86 (SD 0.1). The mean annual total cost to the healthcare system per patient (N=150) was €350,122.7 (SD 118,508.1). Equivalently, the mean cost to patients (n=58) was €3,557.7 (SD 7,901.7), and the mean cost to the caregivers (n=33) was €1,740.4 (SD 3,788.7; n=33; table). Summary/Conclusion: The preliminary results presented here suggest that despite currently available IV C5 inhibition treatment, patients with PNH continue to experience substantial burden of disease, which translates into considerable costs and diminished QoL. Further, this is one of the first reports of outcomes from the PNH-specific QLQ-AA/PNH-54. The persistent unmet need and disease burden requires alternative treatment options and appropriate support.Keywords: Complement, Paroxysmal nocturnal hemoglobinuria (PNH), Patient reported outcomes, Real world data" @default.
• W4385667079 created "2023-08-09" @default.
• W4385667079 creator A5003981865 @default.
• W4385667079 creator A5015233598 @default.
• W4385667079 creator A5016818736 @default.
• W4385667079 creator A5019804033 @default.
• W4385667079 creator A5029141783 @default.
• W4385667079 creator A5045248057 @default.
• W4385667079 creator A5051381067 @default.
• W4385667079 creator A5055188307 @default.
• W4385667079 creator A5056433537 @default.
• W4385667079 creator A5073889590 @default.
• W4385667079 creator A5089834699 @default.
• W4385667079 creator A5092614013 @default.
• W4385667079 creator A5092614014 @default.
• W4385667079 date "2023-08-01" @default.
• W4385667079 modified "2023-10-01" @default.
• W4385667079 title "P783: CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN IN PATIENTS WITH PNH RECEIVING C5 INHIBITION TREATMENT ACROSS UK, GERMANY, AND FRANCE. INSIGHTS FROM THE COMMODORE BURDEN OF ILLNESS STUDY" @default.
• W4385667079 doi "https://doi.org/10.1097/01.hs9.0000970036.35289.96" @default.
• W4385667079 hasPublicationYear "2023" @default.
• W4385667079 type Work @default.
• W4385667079 citedByCount "0" @default.
• W4385667079 crossrefType "journal-article" @default.
• W4385667079 hasAuthorship W4385667079A5003981865 @default.
• W4385667079 hasAuthorship W4385667079A5015233598 @default.
• W4385667079 hasAuthorship W4385667079A5016818736 @default.
• W4385667079 hasAuthorship W4385667079A5019804033 @default.
• W4385667079 hasAuthorship W4385667079A5029141783 @default.
• W4385667079 hasAuthorship W4385667079A5045248057 @default.
• W4385667079 hasAuthorship W4385667079A5051381067 @default.
• W4385667079 hasAuthorship W4385667079A5055188307 @default.
• W4385667079 hasAuthorship W4385667079A5056433537 @default.
• W4385667079 hasAuthorship W4385667079A5073889590 @default.
• W4385667079 hasAuthorship W4385667079A5089834699 @default.
• W4385667079 hasAuthorship W4385667079A5092614013 @default.
• W4385667079 hasAuthorship W4385667079A5092614014 @default.
• W4385667079 hasBestOaLocation W43856670791 @default.
• W4385667079 hasConcept C144024400 @default.
• W4385667079 hasConcept C159110408 @default.
• W4385667079 hasConcept C187212893 @default.
• W4385667079 hasConcept C190248442 @default.
• W4385667079 hasConcept C2779951463 @default.
• W4385667079 hasConcept C36289849 @default.
• W4385667079 hasConcept C512399662 @default.
• W4385667079 hasConcept C71924100 @default.
• W4385667079 hasConcept C74196892 @default.
• W4385667079 hasConceptScore W4385667079C144024400 @default.
• W4385667079 hasConceptScore W4385667079C159110408 @default.
• W4385667079 hasConceptScore W4385667079C187212893 @default.
• W4385667079 hasConceptScore W4385667079C190248442 @default.
• W4385667079 hasConceptScore W4385667079C2779951463 @default.
• W4385667079 hasConceptScore W4385667079C36289849 @default.
• W4385667079 hasConceptScore W4385667079C512399662 @default.
• W4385667079 hasConceptScore W4385667079C71924100 @default.
• W4385667079 hasConceptScore W4385667079C74196892 @default.
• W4385667079 hasIssue "S3" @default.
• W4385667079 hasLocation W43856670791 @default.
• W4385667079 hasLocation W43856670792 @default.
• W4385667079 hasOpenAccess W4385667079 @default.
• W4385667079 hasPrimaryLocation W43856670791 @default.
• W4385667079 hasRelatedWork W1969066409 @default.
• W4385667079 hasRelatedWork W2132185073 @default.
• W4385667079 hasRelatedWork W2138127085 @default.
• W4385667079 hasRelatedWork W2748952813 @default.
• W4385667079 hasRelatedWork W2806889407 @default.
• W4385667079 hasRelatedWork W2899084033 @default.
• W4385667079 hasRelatedWork W2976372530 @default.
• W4385667079 hasRelatedWork W3031052312 @default.
• W4385667079 hasRelatedWork W3156643459 @default.
• W4385667079 hasRelatedWork W4306318783 @default.
• W4385667079 hasVolume "7" @default.
• W4385667079 isParatext "false" @default.
• W4385667079 isRetracted "false" @default.
• W4385667079 workType "article" @default.